The lack of clear guidance from the US Food and Drug Administration regarding KRAS testing to target treatment with anti-EGFR monoclonal antibodies for colorectal cancer is affecting sales of such drugs and putting drugmakers in a difficult spot with regard to what they can and cannot say to doctors.

During an earnings call Last week, BMS said confusion over KRAS testing caused fourth-quarter US sales of its colorectal cancer drug Erbitux to slide 2 percent to $179 million from the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.